
Anders Cervin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4036740/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longâ€acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. International Forum of Allergy and Rhinology, 2022, 12, 147-159.	2.8	10
2	Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placeboâ€controlled crossover trial. Clinical and Experimental Allergy, 2022, 52, 774-783.	2.9	10
3	COVIDâ€19 swabâ€related skull base injury. Medical Journal of Australia, 2021, 214, 457.	1.7	12
4	Panel 4: Recent advances in understanding the natural history of the otitis media microbiome and its response to environmental pressures. International Journal of Pediatric Otorhinolaryngology, 2020, 130, 109836.	1.0	16
5	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, The, 2019, 394, 1638-1650.	13.7	812
6	Inflammation and Endotyping in Chronic Rhinosinusitis—A Paradigm Shift. Medicina (Lithuania), 2019, 55, 95.	2.0	48
7	Phase 1 clinical study to assess the safety of a novel drug delivery system providing longâ€ŧerm topical steroid therapy for chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2019, 9, 378-387.	2.8	13
8	Probiotics in the treatment of otitis media. The past, the present and the future. International Journal of Pediatric Otorhinolaryngology, 2019, 116, 135-140.	1.0	12
9	Oral corticosteroids for painful acute otitis externa (swimmer's ear): A triple-blind randomised controlled trial. Australian Journal of General Practice, 2019, 48, 565-572.	0.8	4
10	Long-term patient-related outcome measures of septoplasty: a systematic review. European Archives of Oto-Rhino-Laryngology, 2018, 275, 1039-1048.	1.6	30
11	The unsolved problem of otitis media in indigenous populations: a systematic review of upper respiratory and middle ear microbiology in indigenous children with otitis media. Microbiome, 2018, 6, 199.	11.1	28
12	Tonsillectomy or tonsillotomy? A systematic review for paediatric sleep-disordered breathing. International Journal of Pediatric Otorhinolaryngology, 2017, 103, 41-50.	1.0	42
13	Quality of Life and Work Capacity Are Unrelated to Approach or Complications After Pituitary Surgery. World Neurosurgery, 2017, 108, 24-32.	1.3	4
14	Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: A randomized controlled trial. Laryngoscope Investigative Otolaryngology, 2017, 2, 410-416.	1.5	45
15	Draft Genome Sequence of the Oral Commensal Streptococcus oralis 89a with Interference Activity against Respiratory Pathogens. Genome Announcements, 2016, 4, .	0.8	5
16	Effects of a honeybee lactic acid bacterial microbiome on human nasal symptoms, commensals, and biomarkers. International Forum of Allergy and Rhinology, 2016, 6, 956-963.	2.8	25
17	Chronic rhinosinusitis: a microbiome in dysbiosis and the search for alternative treatment options. Microbiology Australia, 2016, 37, 149.	0.4	20
18	Draft Genome Sequences of Burkholderia pseudomallei and Staphylococcus aureus, Isolated from a Patient with Chronic Rhinosinusitis. Genome Announcements, 2015, 3, .	0.8	6

ANDERS CERVIN

#	Article	IF	CITATIONS
19	Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study. Inflammation Research, 2015, 64, 903-915.	4.0	24
20	Efficacy and Safety of Long-Term Antibiotics (Macrolides) for the Treatment of Chronic Rhinosinusitis. Current Allergy and Asthma Reports, 2014, 14, 416.	5.3	40
21	Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respiratory Research, 2012, 13, 53.	3.6	45
22	The importance of side difference in nasal obstruction and rhinomanometry: a retrospective correlation of symptoms and rhinomanometry in 1000 patients. Clinical Otolaryngology, 2012, 37, 17-22.	1.2	21
23	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	1.3	1,086
24	European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology Supplement, 2012, 23, 3 p preceding table of contents, 1-298.	6.0	506
25	NOD-like receptors in the human upper airways: a potential role in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 621-628.	5.7	34
26	Can we always trust rhinomanometry?. Rhinology, 2011, 49, 46-52.	1.3	17
27	Allergic rhinitis and the common cold – high cost to society. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 776-783.	5.7	137
28	Genes regulating molecular and cellular functions in noninfectious nonallergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1301-1308.	5.7	5
29	Effects of longâ€ŧerm clarithromycin treatment on lavageâ€fluid markers of inflammation in chronic rhinosinusitis. Clinical Physiology and Functional Imaging, 2009, 29, 136-142.	1.2	31
30	Macrolides and Their Role in the Treatment of Chronic Rhinosinusitis. , 2009, , 295-305.		1
31	Macrolide therapy of chronic rhinosinusitis. Rhinology, 2007, 45, 259-67.	1.3	14
32	A Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial of Macrolide in the Treatment of Chronic Rhinosinusitis. Laryngoscope, 2006, 116, 189-193.	2.0	285
33	Anti-inflammatory Effects of Macrolide Antibiotics in the Treatment of Chronic Rhinosinusitis. Otolaryngologic Clinics of North America, 2005, 38, 1339-1350.	1.1	27
34	Effect of Clarithromycin on Nuclear Factor-l [°] B and Transforming Growth Factor-l ² in Chronic Rhinosinusitis. Laryngoscope, 2004, 114, 286-290.	2.0	51
35	Nasal Septal Perforations during Treatment with Topical Nasal Glucocorticosteroids Are Generally Not Associated with Contact Allergy to Steroids. Orl, 2003, 65, 103-105.	1.1	8
36	The Paranasal Sinuses as Reservoirs for Nitric Oxide. Acta Oto-Laryngologica, 2002, 122, 861-865.	0.9	30

ANDERS CERVIN

#	Article	IF	CITATIONS
37	A Decrease in Maxillary Sinus Pressure, as Seen in Upper Airway Allergy or Infection, Results in an Increase in Upper Airway Nitric Oxide Levels. Acta Oto-Laryngologica, 2002, 122, 520-523.	0.9	8
38	The Paranasal Sinuses as Reservoirs for Nitric Oxide. Acta Oto-Laryngologica, 2002, 122, 861-865.	0.9	41
39	One‥ear Lowâ€Dose Erythromycin Treatment of Persistent Chronic Sinusitis after Sinus Surgery: Clinical Outcome and Effects on Mucociliary Parameters and Nasal Nitric Oxide. Otolaryngology - Head and Neck Surgery, 2002, 126, 481-489.	1.9	82
40	Acute Exudative Inflammation and Nasally Exhaled Nitric Oxide Are Two Independent Phenomena. Orl, 2002, 64, 26-31.	1.1	0
41	Clarithromycin and Prednisolone Inhibit Cytokine Production in Chronic Rhinosinusitis. Laryngoscope, 2002, 112, 1827-1830.	2.0	79
42	The paranasal sinuses as reservoirs for nitric oxide. Acta Oto-Laryngologica, 2002, 122, 861-5.	0.9	6
43	Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement?. Scandinavian Journal of Clinical and Laboratory Investigation, 2001, 61, 459-470.	1.2	16
44	The Anti-inflammatory Effect of Erythromycin and its Derivatives, with Special Reference to Nasal Polyposis and Chronic Sinusitis. Acta Oto-Laryngologica, 2001, 121, 83-92.	0.9	71
45	Functional Effects of Neuropeptide Y Receptors on Blood Flow and Nitric Oxide Levels in the Human Nose. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1724-1728.	5.6	29
46	Effects on the Ciliated Epithelium of Protein D–Producing and –Nonproducing NontypeableHaemophilus influenzaein Nasopharyngeal Tissue Cultures. Journal of Infectious Diseases, 1999, 180, 737-746.	4.0	63
47	The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro. Auris Nasus Larynx, 1998, 25, 269-276.	1.2	15
48	Nitric Oxide is a Regulator of Mucociliary Activity in the Upper Respiratory Tract. Otolaryngology - Head and Neck Surgery, 1998, 119, 278-287.	1.9	84
49	Changes in mucociliary activity may be used to investigate the airway-irritating potency of volatile anaesthetics. British Journal of Anaesthesia, 1998, 80, 475-480.	3.4	26
50	Nitric Oxide (NO) Production in the Upper Airways is Decreased in Chronic Sinusitis. Acta Oto-Laryngologica, 1997, 117, 113-117.	0.9	127
51	Low Levels of Nasal Nitric Oxide (NO) Correlate to Impaired Mucociliary Function in the Upper Airways. Acta Oto-Laryngologica, 1997, 117, 728-734.	0.9	73
52	Recordings of Mucociliary Activity in Vivo: Benefit of Fast Fourier Transformation of the Photoelectric Signal. Annals of Otology, Rhinology and Laryngology, 1996, 105, 734-745.	1.1	5
53	Sinonasal T-cell Lymphoma and Wegener's Granulomatosis: Aspects in Early Differential Diagnosis. American Journal of Rhinology & Allergy, 1996, 10, 239-246.	2.2	0
54	Cyclic Adenosine Monophosphate Stimulation of Mucociliary Activity in the Upper Airways in Vivo. Annals of Otology, Rhinology and Laryngology, 1995, 104, 388-393.	1.1	4

ANDERS CERVIN

#	Article	IF	CITATIONS
55	Neuropeptide Y in the Rabbit Maxillary Sinus Modulates Cholinergic Acceleration of Mucociliary Activity. Acta Oto-Laryngologica, 1992, 112, 872-881.	0.9	9
56	Neuropeptide Y 16–36 inhibits mucociliary activity but does not affect blood flow in the rabbit maxillary sinus in vivo. Regulatory Peptides, 1992, 39, 237-246.	1.9	9
57	The Effect of Neuropeptide Y on Mucociliary Activity in the Rabbit Maxillary Sinus. Acta Oto-Laryngologica, 1991, 111, 960-966.	0.9	15
58	Relations between Blood Flow and Mucociliary Activity in the Rabbit Maxillary Sinus. Acta Oto-Laryngologica, 1988, 105, 350-356.	0.9	17
59	VIP Potentiates Cholinergic Effects on the Mucociliary System in the Maxillary Sinus. Otolaryngology - Head and Neck Surgery, 1988, 99, 401-407.	1.9	6